The information in this section is intended for visitors outside the United States.
Gilead Sciences to Present at the Cowen and Company 35th Annual Health Care Conference on Tuesday, March 3
Gilead Announces Phase 3 Results for Investigational Once-Daily Single Tablet HIV Regimen Containing Tenofovir Alafenamide (TAF)
Gilead Announces SVR12 Rates From Phase 3 Study Evaluating Harvoni® for the Treatment of Chronic Hepatitis C in Patients Co-Infected With HIV
2013 Annual Review